We have developed an innovative and proprietary platform for next-generation CAR-engineered cell therapies (CAR macrophage therapies) with great therapeutic potential for solid tumor (see Fig.3). Our unique and proprietary CAR-MA platform is utilized to manufacture CAR-MA therapies for a wide range of cancers, especially intractable solid tumors. Given to the special characteristics of macrophages, our approach is to use the macrophages isolated from the blood or THP1 macrophage model, and genetically engineer them to express a CAR to guide them to eat the malignant cells. Once CAR-MA preparation is completed, both in vitro assays and in vivo animal testing will be performed to evaluate the efficacy and safety aspects